114 related articles for article (PubMed ID: 33053830)
1. Docking and QSAR of Aminothioureas at the SARS-CoV-2 S-Protein-Human ACE2 Receptor Interface.
Płonka W; Paneth A; Paneth P
Molecules; 2020 Oct; 25(20):. PubMed ID: 33053830
[TBL] [Abstract][Full Text] [Related]
2. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
[TBL] [Abstract][Full Text] [Related]
3. Molecular docking study of potential phytochemicals and their effects on the complex of SARS-CoV2 spike protein and human ACE2.
Basu A; Sarkar A; Maulik U
Sci Rep; 2020 Oct; 10(1):17699. PubMed ID: 33077836
[TBL] [Abstract][Full Text] [Related]
4. Investigation of the genetic variation in ACE2 on the structural recognition by the novel coronavirus (SARS-CoV-2).
Guo X; Chen Z; Xia Y; Lin W; Li H
J Transl Med; 2020 Aug; 18(1):321. PubMed ID: 32831104
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein Binding to ACE2 Receptors from Human, Pets, Farm Animals, and Putative Intermediate Hosts.
Zhai X; Sun J; Yan Z; Zhang J; Zhao J; Zhao Z; Gao Q; He WT; Veit M; Su S
J Virol; 2020 Jul; 94(15):. PubMed ID: 32404529
[TBL] [Abstract][Full Text] [Related]
6. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
Zhu Y; Yu D; Yan H; Chong H; He Y
J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
[TBL] [Abstract][Full Text] [Related]
7. Potential of Flavonoid-Inspired Phytomedicines against COVID-19.
Ngwa W; Kumar R; Thompson D; Lyerly W; Moore R; Reid TE; Lowe H; Toyang N
Molecules; 2020 Jun; 25(11):. PubMed ID: 32545268
[TBL] [Abstract][Full Text] [Related]
8. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Fantini J; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156
[TBL] [Abstract][Full Text] [Related]
9. Structure-based drug designing and immunoinformatics approach for SARS-CoV-2.
Panda PK; Arul MN; Patel P; Verma SK; Luo W; Rubahn HG; Mishra YK; Suar M; Ahuja R
Sci Adv; 2020 Jul; 6(28):eabb8097. PubMed ID: 32691011
[TBL] [Abstract][Full Text] [Related]
10. Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors.
Romeo A; Iacovelli F; Falconi M
Virus Res; 2020 Sep; 286():198068. PubMed ID: 32565126
[TBL] [Abstract][Full Text] [Related]
11. Highly conserved binding region of ACE2 as a receptor for SARS-CoV-2 between humans and mammals.
Hayashi T; Abiko K; Mandai M; Yaegashi N; Konishi I
Vet Q; 2020 Dec; 40(1):243-249. PubMed ID: 32921279
[TBL] [Abstract][Full Text] [Related]
12. In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19.
Vardhan S; Sahoo SK
Comput Biol Med; 2020 Sep; 124():103936. PubMed ID: 32738628
[TBL] [Abstract][Full Text] [Related]
13. Molecular basis for drug repurposing to study the interface of the S protein in SARS-CoV-2 and human ACE2 through docking, characterization, and molecular dynamics for natural drug candidates.
Alazmi M; Motwalli O
J Mol Model; 2020 Nov; 26(12):338. PubMed ID: 33175236
[TBL] [Abstract][Full Text] [Related]
14. Coevolution, Dynamics and Allostery Conspire in Shaping Cooperative Binding and Signal Transmission of the SARS-CoV-2 Spike Protein with Human Angiotensin-Converting Enzyme 2.
Verkhivker G
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33158276
[TBL] [Abstract][Full Text] [Related]
15. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19.
Choudhary S; Silakari O
Virus Res; 2020 Nov; 289():198146. PubMed ID: 32866534
[TBL] [Abstract][Full Text] [Related]
16. Identification of a druggable binding pocket in the spike protein reveals a key site for existing drugs potentially capable of combating Covid-19 infectivity.
Drew ED; Janes RW
BMC Mol Cell Biol; 2020 Jul; 21(1):49. PubMed ID: 32611313
[TBL] [Abstract][Full Text] [Related]
17. Static all-atom energetic mappings of the SARS-Cov-2 spike protein and dynamic stability analysis of "Up" versus "Down" protomer states.
Peters MH; Bastidas O; Kokron DS; Henze CE
PLoS One; 2020; 15(11):e0241168. PubMed ID: 33170884
[TBL] [Abstract][Full Text] [Related]
18. Salvianolic acid C potently inhibits SARS-CoV-2 infection by blocking the formation of six-helix bundle core of spike protein.
Yang C; Pan X; Xu X; Cheng C; Huang Y; Li L; Jiang S; Xu W; Xiao G; Liu S
Signal Transduct Target Ther; 2020 Oct; 5(1):220. PubMed ID: 33024075
[No Abstract] [Full Text] [Related]
19. Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2.
Zhao X; Chen D; Szabla R; Zheng M; Li G; Du P; Zheng S; Li X; Song C; Li R; Guo JT; Junop M; Zeng H; Lin H
J Virol; 2020 Aug; 94(18):. PubMed ID: 32661139
[TBL] [Abstract][Full Text] [Related]
20. Could a specific ACE2 activator drug improve the clinical outcome of SARS-CoV-2? A potential pharmacological insight.
Nicolau LAD; Nolêto IRSG; Medeiros JVR
Expert Rev Clin Pharmacol; 2020 Aug; 13(8):807-811. PubMed ID: 32686527
[No Abstract] [Full Text] [Related]
[Next] [New Search]